Related Experiment Video
Updated: Apr 1, 2026
05:05
Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
Published on: June 17, 2025
1.5K
Mycophenolate mofetil therapy for pediatric bullous pemphigoid
Lucia Seminario-Vidal, Naveed Sami, Jonathan Miller
1Department of Dermatology, University of Alabama at Birmingham. amy.theos@chsys.org.
Dermatology Online Journal
|October 6, 2015
Summary
Childhood bullous pemphigoid (BP) is rare and usually steroid-responsive. This case highlights mycophenolate mofetil (MMF) as a successful alternative for pediatric BP unresponsive to steroids.
Area of Science:
- Dermatology
- Autoimmune Diseases
- Pediatric Medicine
Background:
- Bullous pemphigoid (BP) is a rare autoimmune blistering condition in children.
- Pediatric BP typically shows a good prognosis with standard corticosteroid therapy.
Observation:
- A toddler presented with severe, treatment-resistant bullous pemphigoid.
- The patient's condition did not improve with conventional topical and oral steroid treatments.
Findings:
- Successful treatment of recalcitrant pediatric bullous pemphigoid was achieved with mycophenolate mofetil (MMF).
- MMF provided a viable therapeutic option for a corticosteroid-unresponsive case.
Implications:
- Mycophenolate mofetil (MMF) represents a promising alternative therapy for pediatric bullous pemphigoid.
- This case expands treatment options for rare, severe pediatric autoimmune blistering diseases.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
682
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
682
01:29Inflammatory Bowel Disease IV: Pharmacological Management
947
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
947
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
333
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
333
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
375
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
375
01:29Drugs for Treatment of Ulcerative Colitis in IBD
635
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
635